Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Haleon PLC ( (GB:HLN) ) has issued an update.
Haleon PLC announced that as of October 31, 2025, it has issued a total of 8,952,353,648 ordinary shares, with 45,930,962 held as treasury shares. This results in 8,906,422,686 ordinary shares with voting rights, a figure crucial for shareholders and others with notification obligations under the FCA’s Disclosure Guidance and Transparency Rules. This update is significant for stakeholders as it impacts the calculation of notifiable interests in the company.
The most recent analyst rating on (GB:HLN) stock is a Buy with a £440.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Spark’s Take on GB:HLN Stock
According to Spark, TipRanks’ AI Analyst, GB:HLN is a Outperform.
Haleon PLC’s overall stock score reflects a strong financial foundation with robust profitability and cash flow, tempered by moderate technical indicators and valuation metrics. The mixed earnings call results, with regional strengths and North American challenges, further influence the score. The company’s strategic focus on innovation and geographic expansion supports a cautiously optimistic outlook.
To see Spark’s full report on GB:HLN stock, click here.
More about Haleon PLC
Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with humanity. The company’s product portfolio includes Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. Haleon is known for its trusted brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren.
Average Trading Volume: 21,017,473
Technical Sentiment Signal: Sell
Current Market Cap: £31.54B
Find detailed analytics on HLN stock on TipRanks’ Stock Analysis page.